The global theranostics market size is expected to be valued at US$ 7.9 billion in 2026 and projected to reach US$ 20.6 billion by 2033, growing at a CAGR of 14.7% between 2026 and 2033. Rapid clinical adoption of radiopharmaceutical-based precision oncology, expanding regulatory approvals for targeted radioligand therapies, and rising integration of molecular imaging with therapeutic decision-making are collectively accelerating this growth.

The U.S. Food and Drug Administration has approved multiple targeted radiotherapeutics in recent years, while the Society of Nuclear Medicine and Molecular Imaging continues to report expanding clinical guidelines supporting theranostic protocols. Growing investment in companion diagnostics and personalized treatment pathways is further reinforcing sustained global demand across diagnostic and therapeutic agent categories.

Drivers - Rising Prevalence of Cancer and Demand for Precision Oncology

The escalating global cancer burden is a primary driver of theranostics adoption, as oncologists increasingly rely on combined diagnostic-therapeutic radiopharmaceuticals to personalize treatment regimens. The World Health Organization estimates that cancer incidence continues to rise worldwide, intensifying demand for precision-targeted interventions such as prostate-specific membrane antigen-based therapies. Clinical bodies including the American Society of Clinical Oncology have incorporated theranostic pathways into treatment guidelines for neuroendocrine tumors and metastatic prostate cancer.

This growing clinical validation, combined with improved patient outcomes reported in peer-reviewed oncology journals, is driving expanded theranostics market adoption across hospitals and specialty cancer centers globally, reinforcing sustained long-term procedural volume growth.

Advancements in Radioisotope Production and Supply Infrastructure

Expanding global radioisotope production capacity is significantly strengthening the theranostics market's supply-side foundation, addressing historical bottlenecks in actinium-225 and lutetium-177 availability. The International Atomic Energy Agency has actively supported member states in scaling medical isotope production infrastructure through technical cooperation programs. Companies such as Curium Pharma and ITM Isotope Technologies Munich have expanded manufacturing capacity to meet rising clinical demand for radioligand therapeutics. This growing production reliability reduces treatment delays and supply disruptions, enabling broader hospital and nuclear medicine center adoption while supporting the commercial scalability of next-generation theranostic agents entering late-stage clinical development worldwide.

Restraints - Limited Radiopharmaceutical Manufacturing and Distribution Infrastructure

Theranostic agents, particularly those based on short half-life isotopes, require specialized manufacturing and rapid cold-chain distribution networks that remain underdeveloped across several regions. The International Atomic Energy Agency has noted persistent regional disparities in radioisotope production capacity, constraining timely patient access. This logistical complexity increases treatment costs and limits theranostics market penetration in emerging economies lacking dedicated nuclear medicine infrastructure and trained radiopharmacy personnel.

Stringent Regulatory Pathways and High Development Costs

Radiopharmaceutical development involves complex regulatory review processes overseen by agencies such as the U.S. Food and Drug Administration and the European Medicines Agency, extending approval timelines considerably compared to conventional pharmaceuticals. High costs associated with isotope sourcing, specialized manufacturing facilities, and radiation safety compliance further elevate development expenditure. These combined factors restrain smaller market entrants from scaling theranostic pipelines, moderating overall competitive diversification within the industry.

Opportunities - Expansion of Radioligand Therapy Pipelines Beyond Oncology

While oncology remains the dominant application, expanding theranostics research into neurology and cardiology presents substantial untapped opportunity for market participants. Academic institutions and pharmaceutical developers are increasingly investigating radiotracer-based diagnostic and therapeutic applications for neurodegenerative conditions, supported by growing publications indexed through the National Institutes of Health.

Companies advancing novel targeted isotopes for amyloid imaging and cardiac perfusion assessment stand to capture significant future demand as clinical validation expands. This diversification beyond oncology-focused pipelines allows theranostics market participants to broaden addressable patient populations while reducing dependency on a single therapeutic category, strengthening long-term commercial resilience across diverse disease indications through the forecast period.

Growing Investment and Strategic Partnerships in Radiopharmaceutical Development

Rising capital investment and strategic collaborations between pharmaceutical majors and specialized radiopharmaceutical developers present a significant growth opportunity within the theranostics market. Companies such as Novartis and Telix Pharmaceuticals have pursued acquisitions and partnerships to strengthen their radioligand therapy pipelines and manufacturing capabilities. Increasing venture funding directed toward companies like RayzeBio further underscores investor confidence in the sector's commercial trajectory. This influx of capital is accelerating pipeline development, expanding global manufacturing networks, and enabling faster clinical translation of next-generation theranostic agents, positioning well-capitalized companies to capture disproportionate future market share as demand accelerates worldwide.

Product Type Analysis

Therapeutic agents accounted for the leading share of the theranostics market at 51% in 2026, driven by rapid clinical adoption of targeted radioligand therapies for oncology indications. Approved therapies utilizing lutetium-177 and actinium-225 isotopes have demonstrated strong clinical efficacy in peer-reviewed publications, reinforcing physician confidence in therapeutic radiopharmaceuticals.

Regulatory validation from the U.S. Food and Drug Administration for prostate-specific membrane antigen-targeted therapies has further accelerated segment adoption across specialty cancer centers. As diagnostic-therapeutic pairing becomes standard clinical practice, therapeutic agents are also projected to remain the fastest-growing product category through the forecast period, supported by expanding indications and growing physician familiarity with radioligand treatment protocols.

Technology Analysis

Molecular imaging led the theranostics market with an estimated 36% share in 2026, serving as the foundational technology enabling precise patient selection and treatment monitoring across radioligand therapy protocols. Positron emission tomography-based imaging using targeted radiotracers allows clinicians to visualize biomarker expression prior to initiating therapeutic intervention, a process central to the theranostics market's precision medicine framework. The Society of Nuclear Medicine and Molecular Imaging has published expanding clinical guidelines supporting molecular imaging-guided treatment selection. Genomics, meanwhile, is emerging as the fastest-growing technology segment, propelled by increasing integration of genetic biomarker profiling into companion diagnostic development for next-generation targeted therapeutics.

North America Theranostics Market Trends and Insights

North America led the global theranostics market, accounting for 43% of revenue in 2026, driven by advanced nuclear medicine infrastructure, favorable reimbursement, and rapid commercialization of radioligand therapies. The region performs more than 20 million nuclear medicine procedures annually, with the United States representing nearly 90% of regional procedure volumes. More than 2,200 PET/CT systems and over 1,800 SPECT/CT systems are installed across North America, supporting broad access to molecular imaging. Growing adoption of PSMA PET imaging and lutetium-177-based therapies, alongside continued regulatory approvals by the U.S. Food and Drug Administration, is strengthening clinical utilization. Expansion of isotope production facilities and radiopharmaceutical manufacturing capacity continues to reinforce North America's leadership in precision oncology and theranostic medicine.

U.S. Theranostics Market Size

The United States dominates the North American theranostics market, contributing more than 85% of regional revenue. The country has over 2,000 PET imaging systems and performs 17–18 million nuclear medicine procedures annually, supported by an extensive network of academic medical centers and specialty cancer hospitals. More than 2,000 accredited PET facilities enable widespread access to advanced molecular imaging. Continued U.S. Food and Drug Administration approvals for radioligand therapies and PSMA-targeted imaging agents have accelerated clinical adoption. Expansion of domestic isotope production, increasing investments in radiopharmaceutical manufacturing, and strong Medicare reimbursement continue to support sustained market growth across oncology care.

Europe Theranostics Market Trends and Insights

Europe accounted for 29% of the global theranostics market in 2026, supported by strong nuclear medicine expertise, coordinated radioisotope supply, and well-established healthcare systems. The region performs nearly 10 million nuclear medicine procedures annually and operates more than 1,300 PET/CT scanners alongside an extensive SPECT imaging network. Increasing adoption of radioligand therapies for prostate cancer and neuroendocrine tumors continues to drive market expansion. Regulatory oversight by the European Medicines Agency and investments in isotope production infrastructure have strengthened the regional supply chain. Collaborative research between academic institutions and radiopharmaceutical manufacturers has accelerated clinical trials, while growing availability of specialized theranostic centers continues to improve patient access across major European countries.

Germany Theranostics Market Size

Germany leads the European theranostics market owing to its advanced nuclear medicine infrastructure and strong radiopharmaceutical manufacturing base. The country operates more than 250 PET/CT systems and maintains one of Europe's largest networks of certified nuclear medicine departments. Germany is home to ITM Isotope Technologies Munich, a leading producer of medical radioisotopes and radiopharmaceuticals. Strong collaboration among universities, cancer centers, and industry supports continuous innovation in targeted radionuclide therapies. Rising adoption of PSMA PET imaging and lutetium-177 therapies, coupled with robust reimbursement policies and clinical research activity, continues to reinforce Germany's leading position within the European market.

U.K. Theranostics Market Size

The United Kingdom represents a significant theranostics market, supported by expanding molecular imaging capacity and increasing National Health Service investment in nuclear medicine. The country has more than 70 PET/CT centers serving oncology and neurological indications, while specialized cancer centers continue to expand radioligand therapy services. Clinical research supported by leading academic institutions has accelerated adoption of targeted radiopharmaceuticals. National treatment pathways increasingly incorporate PSMA PET imaging for prostate cancer management, improving patient selection for therapy. Continued investment in diagnostic infrastructure, research collaborations, and workforce development is strengthening nationwide access to theranostic procedures and supporting long-term market growth.

France Theranostics Market Size

France maintains a strong position in the European theranostics market through its established nuclear medicine network and active radiopharmaceutical research ecosystem. The country operates more than 180 PET imaging systems, supporting growing demand for molecular imaging in oncology. Collaboration between university hospitals, research organizations, and industry continues to advance clinical development of targeted radiopharmaceuticals. Increasing adoption of lutetium-177-based therapies for neuroendocrine tumors and prostate cancer is expanding treatment availability nationwide. Government investment in cancer care modernization, together with strong clinical expertise and growing participation in multinational clinical trials, continues to strengthen France's position in the regional theranostics market.

Asia-Pacific Theranostics Market Trends and Insights

Asia-Pacific is projected to register the fastest CAGR through 2033, accounting for 21% of the global theranostics market in 2026. The region operates more than 1,600 PET scanners and over 3,500 SPECT systems, with continuous investment in advanced molecular imaging infrastructure. Rising cancer incidence, expanding healthcare expenditure, and increasing government support for nuclear medicine are accelerating market growth. China, Japan, South Korea, India, and Australia are investing heavily in domestic radioisotope production and radiopharmaceutical manufacturing. Growing availability of cyclotrons and PET radiopharmacies is improving access to precision oncology. Increasing participation in international clinical trials and expansion of theranostic treatment centers continue to strengthen the region's long-term market potential.

India Theranostics Market Size

India's theranostics market is expanding rapidly, supported by increasing cancer incidence and continuous growth in nuclear medicine infrastructure. The country has more than 500 nuclear medicine facilities and over 150 PET/CT scanners, with additional installations occurring across major metropolitan hospitals. Government initiatives under the Department of Atomic Energy and the Ministry of Health continue to strengthen domestic radioisotope production and improve access to advanced oncology care. Growing availability of lutetium-177 therapies, expanding private hospital investment, and increasing clinical expertise are driving nationwide adoption. Rising awareness of precision medicine is expected to further accelerate demand during the forecast period.

Japan Theranostics Market Size

Japan is one of Asia-Pacific's most established theranostics markets, supported by one of the world's largest molecular imaging infrastructures. The country operates more than 400 PET scanners and maintains extensive cyclotron and radiopharmaceutical production capabilities. Strong regulatory oversight by the Pharmaceuticals and Medical Devices Agency and active participation in radiopharmaceutical research have accelerated clinical adoption. Increasing use of PSMA PET imaging and targeted radionuclide therapies for prostate cancer continues to support market expansion. An aging population, high cancer burden, and advanced hospital infrastructure reinforce sustained demand for precision diagnostic and therapeutic solutions throughout the country.

Southeast Asia Theranostics Market Size

Southeast Asia is emerging as a high-growth theranostics market, led by Singapore, Thailand, and Malaysia. Regional governments are investing in nuclear medicine infrastructure, cyclotron facilities, and oncology centers to improve access to advanced cancer care. Singapore has established itself as a regional hub for molecular imaging and clinical research, while Thailand continues expanding radiopharmaceutical treatment capabilities through major tertiary hospitals. Rising cancer incidence, improving healthcare expenditure, and increasing adoption of PET imaging are supporting market growth. Expanding collaborations with international radiopharmaceutical companies and academic institutions continue to strengthen the region's long-term development in theranostic medicine.

The theranostics market remains moderately consolidated, dominated by established pharmaceutical majors alongside specialized radiopharmaceutical developers competing on isotope supply reliability and clinical pipeline breadth. Leading players are pursuing strategic acquisitions, manufacturing capacity expansion, and academic research collaborations to strengthen radioligand therapy pipelines.

Key differentiators include proprietary isotope sourcing, regulatory approval track record, and integrated diagnostic-therapeutic product offerings. Emerging business models emphasize decentralized radiopharmacy networks and companion diagnostic bundling, reflecting the industry's broader shift toward vertically integrated, precision-medicine-aligned commercial strategies across diagnostic and therapeutic agent portfolios globally.

Key Developments

• July 2026: Radiopharm Theranostics announced that its investigational radiopharmaceutical therapy RAD204 achieved a confirmed durable partial response in an ongoing Phase 1 clinical trial involving patients with advanced solid tumors who had previously received immunotherapy. The response indicated a significant and sustained reduction in tumor burden, demonstrating encouraging early signs of clinical activity.
• July 2026: GE HealthCare and Mayo Clinic announced a new research collaboration to advance the development of personalized cancer treatments through theranostics. The partnership combined GE HealthCare's expertise in molecular imaging and radiopharmaceutical technologies with Mayo Clinic's clinical research capabilities to accelerate innovation in precision oncology.